KR101734507B1 - Ｈｃｖ의 마크로시클릭 프로테아제 억제제를 제조하기 위한 방법 및 중간체 - Google Patents
Ｈｃｖ의 마크로시클릭 프로테아제 억제제를 제조하기 위한 방법 및 중간체 Download PDFInfo
- Publication number
- KR101734507B1 KR101734507B1 KR1020117017333A KR20117017333A KR101734507B1 KR 101734507 B1 KR101734507 B1 KR 101734507B1 KR 1020117017333 A KR1020117017333 A KR 1020117017333A KR 20117017333 A KR20117017333 A KR 20117017333A KR 101734507 B1 KR101734507 B1 KR 101734507B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- solvent
- xxa
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- URMTXXSIHXOVSV-UHFFFAOYSA-N OC(CC(C1)O2)C1C2=O Chemical compound OC(CC(C1)O2)C1C2=O URMTXXSIHXOVSV-UHFFFAOYSA-N 0.000 description 2
- JTZZSQYMACOLNN-VDWJNHBNSA-N CC(C)c1c[s]c(-c2cc(O[C@H](C[C@H]3C(N[C@](C4)([C@@H]4/C=C\CCCCN4C)C(NS(C5CC5)(=O)=O)=O)=O)C[C@H]3C4=O)c(ccc(OC)c3C)c3n2)n1 Chemical compound CC(C)c1c[s]c(-c2cc(O[C@H](C[C@H]3C(N[C@](C4)([C@@H]4/C=C\CCCCN4C)C(NS(C5CC5)(=O)=O)=O)=O)C[C@H]3C4=O)c(ccc(OC)c3C)c3n2)n1 JTZZSQYMACOLNN-VDWJNHBNSA-N 0.000 description 1
- FMAQFVKURVXJJC-UHFFFAOYSA-N COC(C(CC(C1)O2)C1C2=O)=O Chemical compound COC(C(CC(C1)O2)C1C2=O)=O FMAQFVKURVXJJC-UHFFFAOYSA-N 0.000 description 1
- YWHQIVJPIBHBSV-UHFFFAOYSA-N OC(C(CC(C1)O2)C1C2=O)=O Chemical compound OC(C(CC(C1)O2)C1C2=O)=O YWHQIVJPIBHBSV-UHFFFAOYSA-N 0.000 description 1
- RJLBLEIPNSPREJ-RFZPGFLSSA-N OC(C[C@H]1C(O)=O)C[C@H]1C(O)=O Chemical compound OC(C[C@H]1C(O)=O)C[C@H]1C(O)=O RJLBLEIPNSPREJ-RFZPGFLSSA-N 0.000 description 1
- CJSMOECOKYPHSC-RFZPGFLSSA-N OC([C@H](CC(C1)=O)[C@@H]1C(O)=O)=O Chemical compound OC([C@H](CC(C1)=O)[C@@H]1C(O)=O)=O CJSMOECOKYPHSC-RFZPGFLSSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/475—Preparation of carboxylic acid esters by splitting of carbon-to-carbon bonds and redistribution, e.g. disproportionation or migration of groups between different molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Furan Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08172691 | 2008-12-23 | ||
| EP08172691.1 | 2008-12-23 | ||
| PCT/EP2009/067715 WO2010072742A1 (en) | 2008-12-23 | 2009-12-22 | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20110099048A KR20110099048A (ko) | 2011-09-05 |
| KR101734507B1 true KR101734507B1 (ko) | 2017-05-11 |
Family
ID=40548041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117017333A Expired - Fee Related KR101734507B1 (ko) | 2008-12-23 | 2009-12-22 | Ｈｃｖ의 마크로시클릭 프로테아제 억제제를 제조하기 위한 방법 및 중간체 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8927722B2 (enExample) |
| EP (1) | EP2382198B1 (enExample) |
| JP (1) | JP5687631B2 (enExample) |
| KR (1) | KR101734507B1 (enExample) |
| CN (1) | CN102264715B (enExample) |
| AR (1) | AR074863A1 (enExample) |
| AU (1) | AU2009331530B2 (enExample) |
| BR (1) | BRPI0923393B1 (enExample) |
| CA (1) | CA2745565C (enExample) |
| CY (1) | CY1114488T1 (enExample) |
| DK (1) | DK2382198T3 (enExample) |
| ES (1) | ES2429013T3 (enExample) |
| HR (1) | HRP20130906T1 (enExample) |
| IL (1) | IL213246A (enExample) |
| MX (1) | MX2011006764A (enExample) |
| PL (1) | PL2382198T3 (enExample) |
| PT (1) | PT2382198E (enExample) |
| RU (1) | RU2016120007A (enExample) |
| SI (1) | SI2382198T1 (enExample) |
| SM (1) | SMT201300116B (enExample) |
| TW (1) | TWI461424B (enExample) |
| WO (1) | WO2010072742A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011006764A (es) | 2008-12-23 | 2011-08-03 | Ortho Mcneil Janssen Pharm | Procedimiento y compuestos intermedios para preparar un inhibidor de proteasa macrociclico del vhc. |
| EP2758386A1 (en) | 2011-09-22 | 2014-07-30 | Janssen Pharmaceuticals, Inc. | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
| EA201490892A1 (ru) | 2011-10-28 | 2014-08-29 | Янссен Фармасьютикалз, Инк. | Усовершенствованный способ получения промежуточного соединения макроциклического ингибитора tmc 435 протеазы |
| CN103387509B (zh) * | 2012-05-11 | 2016-06-08 | 重庆博腾制药科技股份有限公司 | 一种hcv蛋白酶抑制剂中间体的制备方法 |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| JP6209601B2 (ja) * | 2012-06-08 | 2017-10-04 | ギリアード サイエンシーズ， インコーポレイテッド | フラビウイルス科ウイルスの大環状阻害剤 |
| CA2875718A1 (en) | 2012-06-08 | 2013-12-12 | Selcia Limited | Macrocyclic inhibitors of flaviviridae viruses |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| JP6511432B2 (ja) | 2013-03-15 | 2019-05-15 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃ型肝炎ウイルスの大環状二環式阻害剤 |
| WO2015180253A1 (zh) * | 2014-05-29 | 2015-12-03 | 杭州普晒医药科技有限公司 | 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途 |
| MA41812A (fr) | 2015-03-27 | 2018-01-30 | Janssen Pharmaceuticals Inc | Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008092955A1 (en) * | 2007-02-01 | 2008-08-07 | Tibotec Pharmaceuticals Ltd. | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8300536A (nl) | 1983-02-14 | 1984-09-03 | Oce Andeno Bv | Optisch actief alfa-azido-p-hydroxyfenylazijnzuur en zijn zouten alsmede de bereiding daarvan. |
| JPS6124539A (ja) | 1984-07-11 | 1986-02-03 | Sagami Chem Res Center | 光学活性（ｒ）−２，５，１２−トリヒドロキシ−１，２，３，４−テトラヒドロナフタセン−６，１１−ジオン−２−カルボン酸の取得方法 |
| JP4218040B2 (ja) | 1997-12-26 | 2009-02-04 | 曽田香料株式会社 | 有機酸とアミンの複合塩の製造法 |
| JP3844112B2 (ja) | 2000-08-23 | 2006-11-08 | 高砂香料工業株式会社 | ３，５，６−トリヒドロキシヘキサン酸アンモニウム塩誘導体、及びその製造方法 |
| RS51243B (sr) * | 2004-01-30 | 2010-12-31 | Medivir Ab. | Inhibitori ns-3 serina hcv proteaze |
| CN101146795A (zh) * | 2005-01-21 | 2008-03-19 | 阿斯泰克斯治疗有限公司 | 用于抑制cdk和gsk的吡唑衍生物 |
| PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| DK1919904T3 (da) * | 2005-07-29 | 2014-04-07 | Janssen R & D Ireland | Makrocykliske inhibitorer af hepatitis-c-virus |
| RU2490261C2 (ru) * | 2007-02-08 | 2013-08-20 | Тиботек Фармасьютикалз Лтд. | Макроциклические фенилкарбаматы, ингибирующие hcv |
| MX2011006764A (es) | 2008-12-23 | 2011-08-03 | Ortho Mcneil Janssen Pharm | Procedimiento y compuestos intermedios para preparar un inhibidor de proteasa macrociclico del vhc. |
-
2009
- 2009-12-22 MX MX2011006764A patent/MX2011006764A/es active IP Right Grant
- 2009-12-22 DK DK09801447.5T patent/DK2382198T3/da active
- 2009-12-22 SI SI200930731T patent/SI2382198T1/sl unknown
- 2009-12-22 RU RU2016120007A patent/RU2016120007A/ru not_active Application Discontinuation
- 2009-12-22 WO PCT/EP2009/067715 patent/WO2010072742A1/en not_active Ceased
- 2009-12-22 CN CN200980152851.5A patent/CN102264715B/zh not_active Expired - Fee Related
- 2009-12-22 EP EP09801447.5A patent/EP2382198B1/en active Active
- 2009-12-22 JP JP2011541509A patent/JP5687631B2/ja not_active Expired - Fee Related
- 2009-12-22 CA CA2745565A patent/CA2745565C/en not_active Expired - Fee Related
- 2009-12-22 KR KR1020117017333A patent/KR101734507B1/ko not_active Expired - Fee Related
- 2009-12-22 HR HRP20130906AT patent/HRP20130906T1/hr unknown
- 2009-12-22 PL PL09801447T patent/PL2382198T3/pl unknown
- 2009-12-22 ES ES09801447T patent/ES2429013T3/es active Active
- 2009-12-22 TW TW98144049A patent/TWI461424B/zh not_active IP Right Cessation
- 2009-12-22 PT PT09801447T patent/PT2382198E/pt unknown
- 2009-12-22 AR ARP090105059 patent/AR074863A1/es unknown
- 2009-12-22 US US13/141,715 patent/US8927722B2/en not_active Expired - Fee Related
- 2009-12-22 AU AU2009331530A patent/AU2009331530B2/en not_active Ceased
- 2009-12-22 BR BRPI0923393-8A patent/BRPI0923393B1/pt not_active IP Right Cessation
-
2011
- 2011-05-31 IL IL213246A patent/IL213246A/en not_active IP Right Cessation
-
2013
- 2013-10-10 CY CY20131100890T patent/CY1114488T1/el unknown
- 2013-10-10 SM SM201300116T patent/SMT201300116B/xx unknown
-
2014
- 2014-11-25 US US14/552,550 patent/US9115077B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008092955A1 (en) * | 2007-02-01 | 2008-08-07 | Tibotec Pharmaceuticals Ltd. | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101734507B1 (ko) | Ｈｃｖ의 마크로시클릭 프로테아제 억제제를 제조하기 위한 방법 및 중간체 | |
| KR101598135B1 (ko) | Ｈｃｖ의 마크로사이클릭 프로테아제 억제제의 제조 방법 및 중간체 | |
| RU2628081C2 (ru) | Способы и промежуточные соединения для получения макроциклических ингибиторов протеазы hcv | |
| RU2588132C2 (ru) | Способы и промежуточные соединения для получения макроциклического ингибитора протеазы вируса гепатита с | |
| JP6235473B2 (ja) | 大環状ｈｃｖプロテアーゼ阻害剤を製造するための方法および中間体 | |
| HK1137442B (en) | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv | |
| HK1164839B (en) | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D13-X000 | Search requested |
St.27 status event code: A-1-2-D10-D13-srh-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| D14-X000 | Search report completed |
St.27 status event code: A-1-2-D10-D14-srh-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-4-4-P10-P22-nap-X000 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20200503 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20200503 |